HCID 23500659, 화합물 → HCID 23500726, 화합물
반응식
Cl.C(N1CCCC2(C3C(=CC=CC=3)CN2)C1=O)CC.Cl.[CH2:21]([N:24]1[CH2:29][CH2:28][CH2:27][C:26]2([C:37]3[C:32](=[CH:33][CH:34]=[CH:35][CH:36]=3)[C:31](=[O:38])[NH:30]2)[CH2:25]1)[CH2:22][CH3:23]>>[CH2:21]([N:24]1[CH2:29][CH:28]=[CH:27][C:26]2([C:37]3[C:32](=[CH:33][CH:34]=[CH:35][CH:36]=3)[C:31](=[O:38])[NH:30]2)[CH2:25]1)[CH2:22][CH3:23]참가 물질
3
실험 절차
1′-Propylspiro[isoindoline-3,3′-piperidin]-one hydrochloride. The compound from STEP B (6.60 g) was cyclised according to the general Heck procedure described in EXAMPLE 1 to give an oil which was chromatographed on silica gel with ethyl acetate/n-heptane as the eluent to give 830 mg 1′-propylspiro-[isoindoline-3,3′-1,2,3,6-tetrahydropyridin]-1-one as an oil. This compound was hydrogenated as described in EXAMPLE 1 yielding the free base of the title compound as white crystals. The title compound was also prepared from cyclization of the STEP C compound followed by hydrogenation-debenzylation plus propylation. 13C NMR (CDCl3): δ 169.44, 150.10, 131.77, 131.58, 128.51, 124.14, 121.56, 62.74, 60.87, 60.26, 53.24, 34.88, 23.34, 19.00. 11.82; MS(TSP+) m/z: 245 (M+H+, 100); MS(CI, NH3): 245 (M+H+, 100), 180 (3). MP: 110-112°.
후처리
- custom